Valine Dehydrogenase Detection, Activity Profiling

High‑Precision Valine Dehydrogenase Detection, Activity Profiling, and Kinetic Characterisation Services for Metabolic Engineering, Drug Discovery, and Biocatalysis

Valine dehydrogenase (ValDH, EC 1.4.1.8) is a key enzyme in the branched‑chain amino acid (BCAA) metabolism of microorganisms, plants, and certain invertebrates. It catalyses the reversible, oxidative deamination of L‑valine to 3‑methyl‑2‑oxobutanoate (α‑ketoisovalerate) with the concomitant reduction of NAD(P)⁺ to NAD(P)H. This reaction is pivotal in the biosynthesis of valine and the degradation of branched‑chain amino acids, and ValDH activity is a critical determinant of the carbon and nitrogen flux in industrial fermentation processes, particularly in the production of valine, isobutanol, and other high‑value BCAA‑derived compounds. Furthermore, ValDH is an emerging target in antimicrobial drug discovery, as its inhibition can disrupt the essential metabolism of pathogenic bacteria and fungi. The accurate, sensitive, and comprehensive characterisation of ValDH—encompassing enzyme activity, kinetic parameters, substrate specificity, cofactor preference, protein abundance, and inhibitor sensitivity—is indispensable for metabolic engineering, bioprocess optimisation, drug discovery, and quality control of enzyme preparations. Our specialised detection platform offers a fully validated suite of biochemical, spectrophotometric, and mass spectrometric assays tailored to ValDH from bacterial, fungal, and recombinant sources, delivering the high‑precision, regulatory‑ready data that clients require for research, development, and industrial applications.

Scientific, Biotechnological, and Clinical Rationale for Valine Dehydrogenase Analysis

Clients seeking ValDH detection services are motivated by a range of strategic objectives spanning academic research, industrial biotechnology, and pharmaceutical development. In metabolic engineering and industrial fermentation, the primary need is to quantify the specific activity and cofactor preference of ValDH to predict and optimise the flux towards valine and isobutanol production, enabling the selection of high‑performance strains and fermentation conditions. In enzyme engineering and directed evolution, detailed kinetic parameters (K_m, V_max, k_cat) and substrate specificity profiles are required to assess the impact of mutations and to rank variants for improved activity, altered cofactor specificity, or enhanced stability. In antimicrobial drug discovery, evaluating the inhibitory potency of novel compounds against ValDH is essential for identifying selective inhibitors that can target the BCAA metabolism of pathogenic bacteria (e.g., Mycobacterium tuberculosis, Staphylococcus aureus, Candida spp.). In quality control of enzyme preparations, verifying the specific activity, purity, and stability of recombinant ValDH standards is essential for assay development, diagnostic kit production, and reference material use. In regulatory submissions, comprehensive data on enzyme activity, selectivity, and stability are required for the approval of novel biocatalysts, therapeutics, and fermentation products. Our service is architected to address these diverse needs with a flexible, ISO 17025‑accredited analytical framework that adapts to the specific ValDH orthologue, sample matrix (bacterial lysates, purified recombinant proteins, cell culture supernatants), and client's research, industrial, or regulatory context.

Integrated Analytical Platform for Holistic Valine Dehydrogenase Characterisation

Our analytical platform comprises five interconnected modules that collectively deliver a comprehensive evaluation of ValDH quality, activity, and specificity. The Activity Quantification Module employs a well‑validated continuous spectrophotometric assay monitoring the reduction of NAD(P)⁺ at 340 nm, using L‑valine as the substrate under optimised conditions (pH 9.5‑10.5, appropriate temperature). For higher sensitivity and for samples with interfering absorbance, we use a fluorescence‑based assay with a fluorogenic NAD(P)H‑coupled system, or an LC‑MS/MS assay that directly quantifies the formation of α‑ketoisovalerate. We determine the specific activity (U/mg protein) with precision within ±2% RSD and a limit of detection (LOD) as low as 0.001 U/mL. For detailed kinetic characterisation, we calculate Michaelis‑Menten parameters (K_m for L‑valine and for NAD(P)⁺, V_max, k_cat) and inhibition constants (IC₅₀, K_i) for a panel of known inhibitors (e.g., branched‑chain amino acid analogues, the valine analogue 2‑amino‑2‑methyl‑1‑propanol) and test compounds, with 95% confidence intervals typically within ±5%. The Cofactor Specificity and Substrate Module evaluates the enzyme's activity towards a panel of branched‑chain amino acids (L‑valine, L‑leucine, L‑isoleucine) and alternative α‑keto acids, as well as its preference for NAD⁺ versus NADP⁺, generating a specificity fingerprint that can distinguish between ValDH and related dehydrogenases (e.g., leucine dehydrogenase, glutamate dehydrogenase). The Protein Quantitation and Purity Module uses ELISA with specific antibodies (anti‑ValDH) to quantify protein abundance, providing LOQs of 0.05 ng/mg of total protein and inter‑assay precision < 5%. For absolute quantitation and to confirm the presence of the correct subunit composition (homo‑ or hetero‑oligomer), we use LC‑MS/MS‑based targeted proteomics (PRM) with stable isotope‑labelled peptide standards, achieving LOQs in the low fmol/mg range, and native PAGE and size‑exclusion chromatography (SEC‑HPLC) to assess the native oligomeric state. The Inhibitor and Drug Interaction Module evaluates the effect of test compounds on ValDH activity using the primary activity assay, providing mechanism‑of‑action analysis (competitive, uncompetitive, or mixed) and binding affinity measurements by surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC), with K_D values in the low nM range. The Stability and Formulation Module subjects the enzyme to accelerated aging conditions (temperatures from 2°C to 50°C, pH 4‑10, and various ionic strengths) and monitors residual activity, aggregation (by SEC‑HPLC), and conformational integrity (by CD spectroscopy) over time. Using Arrhenius modelling and deactivation kinetics, we predict shelf‑life and identify critical degradation pathways (e.g., deamidation, oxidation, aggregation). All modules are validated with reference ValDH standards (commercial or in‑house) and include rigorous quality controls (system suitability, blank subtraction, and replicate analyses).

Unmatched Analytical Sensitivity, Specificity, and Mechanistic Depth

Our platform consistently delivers performance that surpasses typical industry and academic standards. In activity assays, we achieve signal‑to‑noise ratios > 300:1 at the LOD, with linearity over four orders of magnitude and Z’‑factors consistently > 0.8, making our assays highly robust for high‑throughput screening. Our kinetic fitting software uses global non‑linear regression to provide precise estimates of K_m and V_max, with residual errors < 2%. For protein quantitation by PRM, our chromatographic gradient resolves ValDH‑specific peptides with retention time reproducibility < 0.5% RSD and peak area precision < 3%. In inhibitor studies, we perform full dose‑response curves with at least 8 concentrations in triplicate, and we provide Dixon plots and Cornish‑Bowden analyses to determine the mechanism of inhibition. Additionally, we offer isothermal titration calorimetry (ITC) to measure the binding thermodynamics of inhibitors, providing ΔH, ΔS, and binding stoichiometry with precision within ±2%. For clients requiring detailed structural insight, we perform hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) to map ligand‑binding sites and conformational changes. This multi‑dimensional data set enables our clients to not only quantify ValDH activity but also to understand the molecular basis of substrate recognition, catalytic mechanism, cofactor specificity, and inhibition, facilitating the rational design of more efficient biocatalysts and selective antimicrobial agents.

Distinctive Advantages of Our Valine Dehydrogenase Detection Service

Our service provides several unique benefits that directly address client challenges. First, we have developed matrix‑specific sample preparation protocols for a wide variety of ValDH sources—including bacterial lysates, purified recombinant proteins, and cell culture supernatants—that effectively preserve enzyme activity and protein integrity, achieving recoveries > 95% for all tested matrices. Second, we maintain a comprehensive reference library of ValDH orthologues (from Bacillus, Streptomyces, Pseudomonas, and eukaryotic sources) and their known kinetic and inhibitor data, enabling rapid method setup and confident benchmarking. Third, we offer a rapid screening service using a microplate‑based NADPH‑coupled assay that provides semi‑quantitative activity data within 1 hour of sample receipt—ideal for high‑throughput screening of mutant libraries, fermentation conditions, or compound libraries. Fourth, our customised kinetic and inhibition studies can be tailored to simulate physiological or industrial conditions, including the presence of alternative amino acids, cofactor regeneration systems, and relevant pH/temperature ranges. Fifth, we provide integrated data interpretation that links enzyme activity, cofactor specificity, and inhibition profiles to biological or industrial outcomes (e.g., fermentation yield, antimicrobial potency, biocatalytic efficiency), enabling clients to make informed decisions on strain selection, process optimisation, and drug development. Sixth, all our methods comply with ICH M10, FDA, and EMA guidelines on bioanalytical method validation, and we supply full validation dossiers (specificity, linearity, accuracy, precision, LOD, LOQ, robustness) along with detailed SOPs, ensuring that our data are readily accepted by regulatory authorities. Our team of enzymologists, bioprocess engineers, and pharmacologists provides consultative interpretation, helping clients to design follow‑up experiments, predict in vivo outcomes, and support regulatory submissions.

Advanced Data Integration, Predictive Modeling, and Reporting

Our reporting transforms analytical data into strategic decision‑making knowledge. We deliver a comprehensive final report that includes: (i) an executive dashboard with key metrics (specific activity, K_m, k_cat, K_i, cofactor specificity ratio, and stability half‑life) presented as concise scorecards; (ii) a detailed analytical section containing raw data, calibration curves, kinetic fits, and chromatograms; (iii) a statistical comparison of samples against reference standards or historical data, with p‑values and confidence intervals; and (iv) an interpretive narrative that contextualises the results—for example, explaining how a low IC₅₀ indicates a potent and selective ValDH inhibitor, or how a shift in cofactor preference may affect the enzyme's utility in a whole‑cell biotransformation. For clients with multiple compounds, samples, or time‑points, we provide multivariate analysis (PCA, PLS‑DA) to identify the most influential parameters and to guide selection. We also offer predictive models that estimate in vivo biocatalytic performance or antimicrobial efficacy based on in vitro ValDH data, using our internally developed machine learning tools. All raw data files (e.g., .xlsx, .raw, .cdf) are supplied to ensure full transparency and re‑analysis capability.

Broad Applications Across Metabolic Engineering, Drug Discovery, and Biocatalysis

The versatility of our ValDH detection service spans a wide range of sectors. In industrial biotechnology and metabolic engineering, we quantify ValDH activity to optimise the production of valine, isobutanol, and other BCAA‑derived compounds in microbial cell factories. In pharmaceutical and biotech R&D, our assays are critical for target validation, lead optimisation, and selectivity profiling of novel anti‑infective agents targeting bacterial ValDH. In biocatalysis and synthetic chemistry, we characterise ValDH variants for the enantioselective synthesis of chiral amino acids and α‑keto acids. In enzyme manufacturing, our purity and stability testing ensure product reliability and regulatory compliance. In academic research, our comprehensive profiling supports publication‑quality studies on enzyme mechanism, evolution, and regulation. In contract research organisations (CROs), our services provide robust data to support regulatory submissions. Our ability to tailor the analytical package to the specific ValDH orthologue, sample type, and regulatory framework ensures that we serve a diverse global clientele with scientific rigour and practical relevance.

Commitment to Innovation, Quality, and Client Partnership

We are dedicated to advancing ValDH analytics through continuous technological improvement. Our current R&D includes the development of microfluidic‑based single‑enzyme activity assays for ultra‑sensitive detection, and the application of deep learning algorithms to predict substrate specificity and inhibition from primary sequence data. We actively participate in inter‑laboratory proficiency testing for enzyme activity and protein analysis, and we contribute to the development of reference standards for amino acid dehydrogenases. Our quality management system is ISO 9001 and ISO 17025 certified, and we follow GLP for all regulatory studies. We offer flexible engagement models—from single‑sample analysis to multi‑year collaborative projects—with dedicated project managers, volume discounts, and priority handling for time‑sensitive samples. Our global logistics provide specialised shipping kits (with stabilising buffers and temperature control) to preserve enzyme activity during transit. Turnaround times range from 1 business day for rapid screening to 14 business days for comprehensive kinetic, proteomic, and inhibition profiling. We maintain open communication, providing preliminary results upon request and final reports with expert commentary. Our success is measured by the confidence our clients have in their data and their ability to advance research, development, and industrial production. We invite you to partner with us to unlock the full potential of your valine dehydrogenase research.

In summary, our valine dehydrogenase detection service delivers a comprehensive, precise, and application‑oriented analytical solution that integrates activity quantification, cofactor specificity profiling, substrate specificity evaluation, inhibitor screening, protein quantitation, and stability assessment. By combining advanced instrumentation with deep expertise in amino acid dehydrogenases and biotransformations, we empower our clients to optimise metabolic pathways, develop selective antimicrobial agents, and ensure the quality of biocatalytic products. We look forward to supporting your ValDH analysis needs with our state‑of‑the‑art analytical platform.